NCT03163381 is a Phase 2 clinical trial of Apatinib in Osteosarcoma, Advanced, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT03163381?

NCT03163381 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT03163381?

Interventions in NCT03163381: Apatinib.

What condition does NCT03163381 study?

NCT03163381 studies Osteosarcoma, Advanced.

Is NCT03163381 still recruiting?

NCT03163381 is currently status unknown. Last updated 23 May 2017.

Last reviewed 2017-05-23 · How we verify

NCT03163381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Status unknown Phase 2 Last updated 23 May 2017

What this trial tests

Phase 2 trial testing Apatinib in Osteosarcoma, Advanced in 40 participants. Status unknown.

Timeline

11 April 2017

Primary endpoint
11 October 2017

11 April 2019

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	11 April 2017
Primary completion	11 October 2017
Estimated completion	11 April 2019
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →

Conditions studied

Osteosarcoma, Advanced — all drugs for Osteosarcoma, Advanced →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Osteosarcoma, Advanced. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Apatinib as targeted therapy for sarcoma.
Li F, Liao Z, Zhang C, Zhao J, et al · · 2018 · cited 16× · PMID 29849960 · DOI 10.18632/oncotarget.24647
Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.
Xie L, Xu J, Guo W, Wang Z, et al · · 2021 · cited 9× · PMID 34367981 · DOI 10.3389/fonc.2021.696865
The changing landscape of phase II/III metastatic sarcoma clinical trials-analysis of ClinicalTrials.gov.
Que Y, Xiao W, Xu BS, Wen XZ, et al · · 2018 · cited 7× · PMID 30545340 · DOI 10.1186/s12885-018-5163-2
A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Huang H, Zhang H, Cao B. · · 2024 · cited 3× · PMID 38211967 · DOI 10.1111/1759-7714.15208

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03163381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 23 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03163381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing